2602-P: Cardiometabolic Risk Trajectories On and After Antiobesity Medication Use

Introduction and Objective: The landscape of weight management has changed with incretin mimetic anti-obesity medications (AOM). However, health profiles following discontinuation remain poorly understood. We summarized the cardiometabolic risk trajectories on AOM use and after discontinuation. Methods: A retrospective observational study was conducted using Merative MarketScan health claims linked with Health Risk Assessment data. Adults who filled prescriptions for incretin memetic AOMs between January 2016 and September 2024 were included. Discontinuation was defined as the end of the AOM supply. Individuals with records for body mass index (BMI), systolic blood pressure (SBP), or total blood glucose (BGL) prior to and following the AOM initiation became eligible for the descriptive analysis: mean monthly changes in BMI, SBP, and BGL on AOM use and after discontinuation. Results: The analysis included 20,112 individuals. The unadjusted mean BMI decreased from 36.74 kg/m2 at baseline to 34.55 kg/m2 at month 6 on AOM. The 6-month average BMI gain after discontinuation was +1.62 kg/m2. The respective 6-month changes in SBP and BGL during AOM use were -5.80 mmHg and -5.40 mg/dL. After discontinuation, SBP and BGL rebounded by +1.26 mmHg and +7.4 mg/dL, respectively. Conclusion: A substantial proportion of BMI, SBP, and BGL reductions were lost within 6 months after the AOM discontinuation. Further studies on AOM persistence and its outcomes are warranted to support the efficient AOM use. Disclosure L. Khoja: Other - postdoctoral fellow; Current; Takeda Pharmaceutical Company Limited. M. Alnuman: None. J.Y. Osei: None. D. Touchette: Advisory Panel; Current; Boehringer Ingelheim International GmbH. B. Layden: None. K. Kim: Other - Research Fellowship; Current; Takeda Pharmaceutical Company Limited.